Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2011
December 2011, Vol 2, No 7
December 2011, Vol 2, No 7
AMA Calls for More Transparency in Patient Navigation Programs
By
Caroline Helwick
Patient Navigation
,
Policies & Guidelines
December 2011, Vol 2, No 7
The House of Delegates of the American Medical Association (AMA) laid out guidelines for patient navigator programs during their November 2011 Interim Meeting. The aim is to ensure that patient navigators “enhance, rather than undermine, the delivery of high-quality patient care,” the resolution states.
Read Article
Is Sentinel Lymph Node Biopsy Truly the Standard of Care in Melanoma?
By
Rosemary Frei, MSc
American Pathologists Meeting
December 2011, Vol 2, No 7
Two expert oncologists presented the clinical data in support for and against the use of sentinel lymph node biopsy (SLNB) in melanoma as the standard of care during the 2011 College of American Pathologists annual meeting.
Read Article
Clinical and Economic Impact of Multiple Myeloma
By
Matthew Mitchell, PharmD, MBA
Economics & Value
,
Value-Based Care
,
VBCC Perspectives
December 2011, Vol 2, No 7
The clinical and economic impact of multiple myeloma is tremendous. With the onset of novel therapies used in multiple myeloma, as well as the release of new data demonstrating progression-free survival and overall survival, therapy used in multiple myeloma is now on the radar for payers, despite the relatively low incidence of the disease.
Read Article
Hypofractionated Radiotherapy in Prostate Cancer More Convenient for Patients
By
Phoebe Starr
ASTRO Annual Meeting
December 2011, Vol 2, No 7
Delivering higher doses of external-beam radiation over a shorter period (hypofractionated radiation) was as effective as conventional radiation in preventing treatment failure in men with intermediate- to high-risk prostate cancer.
Read Article
The Pace of Change in Oncology Management Greater than the Sum of Its Parts
By
Lee Goldberg
Oncology
December 2011, Vol 2, No 7
Innovative medications target the molecular structure of cancer cells with increasing precision, resulting in reduced adverse effects. Novel therapies enlist the patients’ own immune systems to defeat cancer. At the same time, as personalized medicine comes of age, improved diagnostic tests match the right patients to these new treatments.
Read Article
Page 4 of 4
1
2
3
4
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma